about
Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory MyopathiesT0001, a variant of TNFR2-Fc fusion protein, exhibits improved Fc effector functions through increased binding to membrane-bound TNFαBiologic agents in the treatment of glomerulonephritides.An overview of developing TNF-α targeted therapy for the treatment of psoriasis.Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison.Secukinumab (AIN-457) for the treatment of Psoriasis.A BioDesign Approach to Obtain High Yields of Biosimilars by Anti-apoptotic Cell Engineering: a Case Study to Increase the Production Yield of Anti-TNF Alpha Producing Recombinant CHO Cells.Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease.Biological drugs for inducing remission in patients with Crohn's disease: determining statistical equivalence according to evidence-based methodsMolecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases.Of patents and patent disputes: The TNFα patent files. Part 1: Humira.Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method.Oxidized low density lipoprotein facilitates tumor necrosis factor‑α mediated chondrocyte death via autophagy pathway.The influence of various therapeutic regimens on early clinical and laboratory response and outcome of children with secondary hemophagocytic lymphohistiocytosis.Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis.IL-12/23p40 overproduction by dendritic cells leads to an increased Th1 and Th17 polarization in a model of Yersinia enterocolitica-induced reactive arthritis in TNFRp55-/- mice.Infliximab alleviates the mortality, mesenteric hypoperfusion, aortic dysfunction, and multiple organ damage in septic rats.Sequentiality of treatment in the rheumatoid arthritis drug programme in the years 2009-2014.Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately respondinSurrogate potency assays: Comparison of binding profiles complements dose response curves for unambiguous assessment of relative potencies.Selective Modulation of TNF-TNFRs Signaling: Insights for Multiple Sclerosis Treatment.
P2860
Q26798209-70187D85-A9A2-4CC0-BCD5-7B2D8C76218EQ36380447-D7C3CB77-86A7-4FB8-BEC6-1973A2B1D3BDQ38514894-04EF48ED-2C9D-4361-A1C1-5DBDD4DF558EQ38569794-170E8026-CC29-4394-9D0D-0CCE10A1B887Q38648826-5EB8201B-BE65-4374-A275-956BD202003DQ38662868-5472FB46-45F9-4AB9-8DAB-3DDFFE5BA91FQ38697887-30FF7DEC-6324-4605-A2FD-E7167AB14494Q39435409-8ACA59EB-FE63-415B-AA45-73C6FABF226AQ40429147-99096274-C5D7-42D2-B8D6-C45210274803Q42323191-CDF42CB8-9DAE-4E1C-A88F-6A4464874385Q47631169-31E255D6-120D-4A4C-A24E-8ECF8846AFC3Q47672593-6EAFC7B2-0352-4C3C-9F33-D92D52A17D0EQ49425306-304EAAC5-6A79-49EC-9522-B2A30961F0C7Q49592363-4A4DDB9B-0E82-44F9-912A-DBA2F88C5612Q52362617-36069AB5-E35F-4B8A-A660-0A54A589B2DEQ52679480-42FC4ACE-37A3-4410-A90D-116F03A10275Q52874596-A9B4B4BF-9A2A-4ADA-BFF4-76C4BA64FF21Q54966198-D07A6E77-5342-4AC8-BC90-3A1AA204D988Q54967818-9F852366-1CF7-488A-ADEC-408BE546C46AQ54988566-0829D756-BB3F-4B3B-9A9B-DDD0BD3CDF83Q55130300-5572F617-C617-4125-A59C-F5B3C5D784F1
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Tumor necrosis factor inhibitors - state of knowledge.
@ast
Tumor necrosis factor inhibitors - state of knowledge.
@en
Tumor necrosis factor inhibitors - state of knowledge.
@nl
type
label
Tumor necrosis factor inhibitors - state of knowledge.
@ast
Tumor necrosis factor inhibitors - state of knowledge.
@en
Tumor necrosis factor inhibitors - state of knowledge.
@nl
prefLabel
Tumor necrosis factor inhibitors - state of knowledge.
@ast
Tumor necrosis factor inhibitors - state of knowledge.
@en
Tumor necrosis factor inhibitors - state of knowledge.
@nl
P2093
P2860
P356
P1476
Tumor necrosis factor inhibitors - state of knowledge.
@en
P2093
Ewa Bałkowiec-Iskra
Krzysztof Lis
Olga Kuzawińska
P2860
P304
P356
10.5114/AOMS.2014.47827
P577
2014-12-01T00:00:00Z